Good morning! Meta's elimination of fact-checking opens the door to misogynistic speech, Jane Fraser faces a test at Citi, ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

Eli Lilly & Co. closed $199.24 short of its 52-week high ($972.53), which the company achieved on August 22nd.

The GCC, to be known as the Lilly Capability Centre India (LCCI), will be the company’s second centre in the country, ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...